Please login to the form below

Not currently logged in
Email:
Password:

Vertex strikes Italian reimbursement deal for Orkambi

AIFA gives the go-ahead for the cystic fibrosis treatment

VertexVertex has struck a market access deal in Italy for its cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor).

The reimbursement agreement with the Italian Medicines Agency (AIFA) will, the Boston-based pharma company said, enable access for hundreds of people in the country.

Simon Bedson, senior vice president and international general manager at Vertex, said: “We are pleased to have reached this agreement on behalf of CF patients in Italy who have been waiting for this important medicine.”

The firm was light on the details of the deal, but said it would add to pricing European pricing and reimbursement agreements in Germany, Austria, Denmark, Ireland and Luxembourg.

However, there are a number of countries with which Vertex has not been able to come to an agreement, among them France and England, whose cost-effectiveness watchdog rejected the drug last year.

Publishing its final appraisal determination NICE said the £104,000 per patient price tag was "too high" for the drug’s “modest” short term benefit, but Vertex is still working on coming to an agreement.

Bedson said: “We continue negotiations with other countries including France and the United Kingdom, and we encourage these national health authorities and government to work quickly with us to achieve reimbursement for all patients who may benefit.”

Orkambi treats cystic fibrosis in patients that have two copies of the f508del mutation and the twice-daily oral is the first medicine to treat the underlying cause of the genetic disease.

Vertex has been involved in a CF research programme since 2000 as a part of collaboration with CFFT, a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

Article by
Gemma Jones

13th July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics